Jessica Hergert | Authors


Combining Camrelizumab, Chemotherapy Leads to Survival Benefit in Esophageal Squamous Cell Carcinoma

July 23, 2021

The frontline combination of camrelizumab and chemotherapy resulted in improved overall survival and progression-free survival and a manageable safety profile compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 Era

July 10, 2021

The rapid issuance of clinical trial guidance, trial modifications and emphasis on inclusivity of diverse racial and ethnic patient populations have opened the door for new opportunities for decentralized clinical trials and real-world data in a post-Covid-19 world

Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer

July 06, 2021

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression.